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It has been shown previously that recombinant virus-like particles (VLPs) of papillomavirus can induce VLP-specific
humoral and cellular immune responses following parenteral administration. To test whether mucosal administration of
bovine papillomavirus type 1 (BPV1) VLPs could produce mucosal as well as systemic immune responses to VLPs, 50 mg
chimeric BPV1 VLPs containing an HPV16 E7 CTL epitope (BPVL1/E7 VLP) was administered intranasally to mice. After two
immunisations, L1-specific serum IgG and IgA were observed. L1-specific IgG and IgA were also found in respiratory and
vaginal secretions. Both serum and mucosal antibody inhibited papillomavirus VLP-induced agglutination of RBC, indicating
that the antibody induced by mucosal immunisation may recognize conformational determinants associated with virus
neutralisation. For comparison, VLPs were given intramuscularly, and systemic and mucosal immune responses were
generally comparable following systemic or mucosal delivery. However, intranasal administration of VLP induced significantly
higher local IgA response in lung, suggesting that mucosally delivered HPV VLP may be more effective for mediating local
mucosal immune responses. Intranasal immunisation with HPV6b L1 VLP produced VLP-specific T proliferative responses
in splenocytes, and immunisation with BPVL1 VLP containing an HPV16 E7 CTL epitope induced E7-specific CTL responses.
We conclude that immunisation with papillomavirus VLPs via mucosal and intramuscular routes, without adjuvant, can elicit
specific antibody at mucosal surfaces and also systemic VLP epitope specific T cell responses. These findings suggest that
mucosally delivered VLPs may offer an alternative HPV VLP vaccine strategy for inducing protective humoral immunity to
anogenital HPV infection, together with cell-mediated immune responses to eliminate any cells which become infected.
© 1998 Academic Press
INTRODUCTION
Viral and bacterial pathogens, including human immu-
nodeficiency virus (HIV), human papillomavirus (HPV),
herpes simplex virus (HSV), Chlamydia trachomatis, and
Neisseria gonorrhoeae, are sexually transmitted dis-
eases that enter the body through the genital mucosa.
Therefore, a major goal of vaccines against these dis-
eases should be to elicit an immune response at the
level of the genital mucosa, which may block, or at least
limit, entry of the pathogen. Ideally, a vaccine should also
stimulate a cytotoxic T cell (CTL) response, which would
offer improved protection by clearing infected cells when
infectious virus penetrates the first line of defense, the
neutralising antibodies.
Papillomavirus (PV) major capsid protein can self-as-
semble into virus-like particles (VLPs) when expressed
in eukaryotic and prokaryotic systems (Zhou et al., 1991;
Kirnbauer et al., 1992; Hagensee et al., 1993; Schiller and
Lowy, 1996; Nardelli-Haefliger et al., 1997). PV VLPs have
been used to elicit high titres of systemic neutralizing
antibodies which provide protection from experimental
challenge with infectious virus in animal papillomavirus
models. As papillomavirus infection is via the mucosal
route, it is of interest to examine if papillomavirus VLPs
can be used as a vaccine to elicit mucosal and systemic
immune responses.
A C-terminal truncation mutant of L1 protein has
been observed to form VLPs (Paintsil et al., 1996), and
up to 60 amino acids can be fused into this region
without disrupting its ability to form VLPs (Mu¨ller et al.,
1997). Thus it is possible to fuse different defined CTL
epitopes, or other immunogenic epitopes, to the C
terminus of PV L1 sequence to construct vaccines
against different diseases. The defined H-2Db-re-
stricted HPV16 E7 CTL epitope (aa 318–327) (Feltkamp
et al., 1993) has been fused to the C terminus of BPV1
L1 sequence and expressed in insect cells by recom-
binant baculovirus. It was demonstrated that this re-
combinant BPV1 L1 protein could spontaneously self-
assemble into VLPs with a morphology very similar to
that of wild-type L1 VLPs and that these VLPs elicit
immunity to PV and to the incorporated CTL epitope
when administered systemically to mice (Greenstone
et al., 1998; Peng et al., 1998). In this paper, we show
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that mice immunised with BPVL1/E7 VLP intranasally
can also elicit cellular and humoral immunity and that
the humoral immunity extends to production of VLP-
specific antibodies at mucosal surface.
RESULTS
Humoral and secretory antibody responses in mice
following nasal immunisation with BPVL1/E7 and
BPVL1/HIVP18 VLPs
Purified BPVL1/E7 (BPV1 VLPs incorporating CTL
epitopes from HPV16E7) and BPVL1/HIVP18 VLPs
(BPVL1 VLP containing a HIV gp120 CTL epitope) have
been examined by immunoblotting and electromicros-
copy. The morphology of those VLPs is similar to that of
BPVL1 VLP (data not shown), indicating that the insertion
of HPV16 E7 or HIV gp120 epitope did not interfere with
the VLP formation. Mice immunised twice intranasally or
intramuscularly with the hybrid VLP developed signifi-
cant anti-BPVL1 antibody titres in serum by 7 days after
the second immunisation. VLP (50 mg) produced serum
IgG, and the titre of serum IgG antibody to BPVL1 VLPs
in the intramuscularly immunized group was higher than
that of sera from mice that received VLPs intranasally
(Fig. 1), indicating that both muscular and mucosal ad-
ministration of papillomavirus VLPs can stimulate a sys-
temic HPV-specific antibody response and that incorpo-
ration of HPV16 E7 and HIV CTL epitopes did not abolish
the immunogenicity of the BPV1 L1 protein conforma-
tional epitopes. As secretion of IgA at mucosal surface
may play a role in protecting the host from pathogens
that infect mucosal membranes, we examined whether
immunisation with VLPs intranasally or intramuscularly,
without adjuvant, could elicit mucosal IgA antibody pro-
duction. Our data showed that mice immunised by alter-
native route in both groups developed mucosal IgA an-
tibody at local (lung) and remote (vaginal tract) mucosal
surfaces (Fig. 1). The IgA titre in lung washes from mice
immunised intranasally was higher than that from the
intramuscular immunised group. The IgA titres in vaginal
washes from mice immunised by either route both was
relatively low. IgG titres in lung and vaginal secretions
were also detected following immunisation by either
route, with the IgG titre in lung being higher than that of
vaginal washes. However, the IgG and IgA titres were
higher in the sera from mice immunized with VLP intra-
muscularly. The absolute IgA reactivity with VLPs in vag-
inal mucosal washings was relatively low, as also indi-
cated by HA inhibition assays (see below), suggesting
that mucosal delivery of VLPs can induce protective local
and remote mucosal as well as systemic immunity to
HPV.
FIG. 1. Capture ELISA assays for detection of BPV-specific antibodies in sera and mucosal secretions from mice received 50 mg BPVL1/E7 VLP.
Diluted (x axis) sera and mucosal secretions are incubated with BPV1 VLPs coated on 96-well plates, and the VLP-specific IgA (top) or IgG (panel)
antibodies were detected with HRP-linked goat anti-mouse antibodies. The OD values are shown on the y axis.
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VLPs induce neutralising antibodies
To assess whether the serum and mucosal anti-
bodies of animals intranasally or intramuscularly
immunised with 50 mg BPVL1/E7 VLP had neutraliz-
ing activity, serum and mucosal secretions were
tested in a hemagglutination inhibition assay which
has been held to correlate with virus neutralisation
(Roden et al., 1995). BPVL1/E7 VLP were mixed with
serial dilutions of serum or of vaginal/lung washes of
immunised mice. A rabbit anti-BPV1 antiserum was
used as a positive control. The serum of immunised
mice showed hemagglutination inhibition (HAI) activ-
ity. The diluted vaginal secretion washes of the both
intramuscularly and intranasally immunized mice
showed HAI activity at a dilution of 1:4. However, the
diluted lung secretion washes of the intranasally im-
munized group showed HAI activity at a dilution of
1:128 and the HAI activity of intramuscularly immu-
nized group was 1:16. No HAI activity was found in the
sera or secretions from nonimmunised mice (Fig. 2).
In vitro T cell proliferation in response to nasal
immunisation with HPV6b L1 VLPs
T cell proliferation to viral capsid antigens has been
observed in animals experimentally infected with pap-
illomavirus. We examined whether mice immunised
with VLP via the mucosal route could produce VLP-
specific systemic T cell responses. Mice were immun-
ised with 30 mg HPV6b L1 VLPs via the nostrils and
were boosted once after 14 days. In two independent
experiments, splenocytes were cultured in the pres-
ence of denatured HPV6b L1 protein for 4 days, and T
cell proliferation assessed as [3H]thymidine incorpo-
ration. The stimulation index (SI) for splenocytes ex-
posed to 20 mg/ml VLPs was 5.6 6 1.0 (3610 6 621/
643 6 64) or 7.2 6 2.1 (4667 6 1372) to 40 mg/ml VLPs,
which was significantly greater than that for spleno-
cytes exposed to ovalbumin [1.6 6 0.1 (1064 6 72/
643 6 64)], demonstrating that intranasal immunisa-
tion with HPV6b L1 VLPs induced a specific T helper
response to the HPV6b L1 protein.
FIG. 2. Inhibition of BPV-1-VLP-induced agglutination of mouse erythrocytes by serum, vaginal, and lung washings from mice immunised
intranasally or intramuscularly with 50 mg BPVL1/E7 hybrid VLPs and the tested dilutions of sera (top) or mucosal washes (bottom) are indicated. The
assay was performed as described under Materials and Methods. All tested sera from VLP-immunised mice inhibited agglutination. Rabbit anti-BPV1
virus antibody was used as a positive control and preimmune mouse serum, vaginal, and lung washing samples were used as negative controls.
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Hybrid BPVL1/HPV16 E7 VLPs can induce a CTL
response
VLP delivered systematically induces CTL response to
defined CTL epitopes incorporated into the VLP L1 pro-
tein (Greenstone et al., 1998; Peng et al., 1998). To test if
VLP delivered by the mucosal route could similarly in-
duce specific T-cell-mediated cytotoxicity activity, the
CTL response to a defined H-2Db-restricted CTL epitope
(HPV16 E7) incorporated within the hybrid BPV-1 VLPs
was observed. C57B1/6J mice were immunised intrana-
sally with 50 mg of BPVL1/E7 or BPVL1/HIVP18 VLPs on
Days 0 and 14. On Day 28, splenocytes were harvested
and expanded in vitro for 3 days in the presence of rIL-2.
CTL activity of the effector T cells was tested on the
E7-transformed EL-4 cells (C2 cell line) or parent EL-4
cells, a negative control to confirm that the cell lysis is
not caused by LAK activity after IL-2 stimulation, by a
standard 51Cr release assay. A CTL response was de-
tected in the BPVL1/E7 groups immunised with 50 mg
BPVL1/E7 VLPs (Fig. 3). Mice immunised with BPVL1/
HIVP18 VLPs did not produce a C2-specific CTL re-
sponse, as expected. These results demonstrate that
immunisation with papillomavirus VLPs through the in-
tranasal route can elicit systemic antigen-specific CTL
responses.
DISCUSSION
In this study, we have shown that mucosal delivery of
VLPs in mice induces both mucosal and systemic hu-
moral immunity and additionally induces cellular immu-
nity to incorporated T epitopes. The low titre of the
vaginal mucosal antibody responses observed reflects in
part the significant dilution factor (.50-fold) inherent in
the technique of vaginal washing. Responses at remote
mucosal surfaces are also held to be of lower titre than
those at the immunisation site, as our data and other
studies have suggested (Hopkins et al., 1995). Measure-
ment of vaginal responses following immunisation at
remote mucosal sites was held desirable for practical
reasons. Although vaginal immunisation is feasible
(Uehling et al., 1997), a local inflammatory response
following intravaginal immunisation might result in local
serum exudation, and therefore assay results obtained
following immunisation by this route might not reflect
local secretory antibody.
Several vaccine candidates induce humoral mucosal
immunity against papillomavirus. HPV16 E7 recombinant
Streptococcus gordonii (Di Fabio et al., 1998) or Salmo-
nella typhimurium (Londono et al., 1996) and HPV L1
recombinant vaccinia (Hagensee et al., 1995) and S.
typhimurium (Nardelli-Haefliger et al., 1997) each elicit
mucosal antibody in mice. A double nasal immunisation
with L1 recombinant Salmonella was effective in induc-
ing L1-specific antibodies that recognized native but not
disassembled VLPs and neutralized HPV16 pseudotyped
virions in an in vitro infectivity assay (Nardelli-Haefliger
et al., 1997). Conformation-dependent anti-VLP IgA and
IgG were also detected in oral and vaginal secretions.
African green monkeys immunised with HPV11 virus-like
particles in aluminum adjuvant by intramuscular injec-
tion mount a high-titre HPV11 VLP-specific antibody re-
sponse, and HPV11-neutralizing IgG antibodies were
also observed in cervical vaginal secretions, but IgA
antibody was not detected (Lowe et al., 1997). Thus the
mode and route of delivery are likely to influence the
nature and magnitude of the induced immune response
following immunisation with HPV VLPs.
We chose to deliver VLP via the nasal route as, follow-
ing four mucosal routes of immunization—oral, nasal,
rectal, and vaginal—the highest titres of mucosal anti-
body were obtained with intranasal immunisation (Hop-
kins et al., 1995), whereas vaginal immunisation gave a
high or low response depending on the estrous status of
the mice at the time of immunisation. The mechanism by
which nasal immunisation induces mucosal and sys-
temic immunity is not clear. Antigen at mucosal surfaces
is taken up by mucosal dendritic cells and carried to the
local mucosal lymphoid tissues, where specific T and B
cells are induced (Husband, 1993). These can move into
cervical and uterine tissues (Roche and Crum, 1991;
Mestecky et al., 1994; Crowley-Nowick et al., 1997),
where polymeric IgA antibodies are produced and trans-
ported across the epithelium. Intraepithelial dendritic
cells in the bronchial epithelium may play a major role in
antigen presentation by taking up antigens in the respi-
ratory epithelium and carrying them to distant draining
lymph nodes, where priming for CTL response occurs
(Hamilton-Easton and Eichelberger, 1995). Papillomavi-
ruses bind to epithelial cells through a6 integrins
(Evander et al., 1997), and activated dendritic cells also
express a6 integrin (Price et al., 1997). This latter finding
FIG. 3. Specific killing of HPV16-E7-transformed EL-4 cell line (C-2)
by CTL bulk cultures generated from mice immunised twice intrana-
sally with hybrid BPVL1/E7 VLP. Splenocytes were cultured with IL-2 for
3 days and used as effector cells in a standard 51Cr release assay.
Specific 51Cr release is shown for effectors from mice intranasally
immunised with 50 mg BPV1-HPV16 E7 VLPs or with 50 mg BPV1/
HIVP18 VLPs. Lysis of untransfected EL-4 cells was, in each case,
,5%.
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may explain why nasal immunisation can trigger both
local and systemic antibody and systemic T cell re-
sponses. Currently, mucosal T cell responses to papillo-
mavirus VLPs are under investigation in our laboratory.
Papillomavirus VLPs have been shown to have strong
immunogenicity in the absence of adjuvants (Roden et
al., 1994; Christensen et al., 1996). We and others have
previously shown that hybrid papillomavirus VLPs con-
taining HPV16 E7 and HIV CTL epitopes can be used as
carriers to present antigens without adjuvant to both
MHC class I and class II pathways, providing a promis-
ing strategy for the design of vaccines to prevent virus
infection (Greenstone et al., 1998; Peng et al., 1998). In
this study, we have demonstrated that papillomavirus
VLPs can also prime antibody and cellular immune re-
sponses via the mucosal route, without adjuvant, sug-
gesting that preservation of the VLP structure to allow
induction of conformation-dependent neutralizing anti-
body responses and to facilitate VLP uptake by antigen-
presenting cells may assist effective design of PV vac-
cines designed to induce local mucosal immunity.
CTL play a role in controlling the initial stage of viral
infection by eliminating virus-infected cells. CTL are ef-
fective in the genital tract for prevention of vaginal infec-
tion, as demonstrated for herpes simplex virus (HSV) by
adoptive transfer of CD81 genital LN cells from donors
immunised with live attenuated HSV (McDermott et al.,
1989). Mucosal immunisation of macaques with VLPs
together with adjuvant elicits virus-specific T cells in the
genital or rectal mucosa as well as draining lymph nodes
(Di Fabio et al., 1998). We immunised mice intranasally
with 50 mg different VLPs and observed a specific CTL
response as well as both systemic and mucosal anti-
body responses in those animals.
Vaccines based on injection of purified papillomavirus
VLPs have been shown to induce type-specific protec-
tion from experimental infection by cottontail rabbit pap-
illomavirus in domestic rabbits and by canine oral pap-
illomavirus in dogs (Breitburd et al., 1995; Suzich et al.,
1995). Passive transfer experiments indicated that pro-
tection is due to the production of virion-neutralizing
antibodies. Thus HPV16 VLP-specific antibodies in cer-
vical secretions could be expected to similarly prevent
sexually transmitted HPV16 infection in humans. How-
ever, it is difficult to predict whether secretory IgA pro-
duced by mucosal lymphoid tissues or serum IgG or a
combination of the two will be most effective in prevent-
ing genital HPV infection. Therefore induction of both
local and systemic antibody responses may be desirable
in a prophylactic genital HPV vaccine, while specific T
cell responses may help to eliminate any cells which are
infected with virus that is not neutralised. Mucosal de-
livery of PV VLP provides an alternative administration
route for a vaccine to induce both mucosal and system-
atic immunity to HPV infection. It would therefore be
worthwhile to consider this route in evaluating potential
vaccines against HPV infection in man.
MATERIALS AND METHODS
Mice and cell lines
Adult female C57BL/6J mice were purchased from
Animal Resource Centre (ARC, Australia). The HPV16 E7
transfected EL4 cell line designated C2 (Tindle et al.,
1995) and the parent EL4 line were maintained in com-
plete RPMI 1640 medium plus 10% fetal bovine serum
(FBS, CSL, Australia).
Construction of recombinant baculovirus and
purification of VLPs
Production and purification of 6b L1 VLPs (Park et al.,
1993) and of BPVL1/E7 and BPV1/HIV1 gp160P18 hybrid
recombinant baculoviruses (Peng et al., 1998) from SF-9
cells infected with the appropriate recombinant baculo-
viruses have been described. In brief, VLPs were purified
from insect cell nuclei by CsCl gradient centrifugation,
and a band with a density of 1.28 g/ml was collected and
dialysed extensively against PBS. The samples were
then used for analysis by transmission electron micros-
copy, and for Western immunoblotting to confirm the
identity and integrity of the VLPs.
Western immunoblot analysis
Protein samples were diluted in SDS–PAGE sample
buffer, boiled at 100°C for 10 min, and electrophoresed
through a 10% SDS–PAGE gel, and then transferred to
nitrocellulose membrane. The membrane was blocked
with 5% skim milk in PBS and probed with the anti-L1
monoclonal antibody MC15 (Kulski et al., 1997) at a
dilution of 1:2000. Bound antibody was detected by in-
cubation of the membrane with horseradish peroxidase-
conjugated, sheep anti-mouse antibody (Silenus, Austra-
lia) at a dilution of 1:1000 and visualised using enhanced
chemiluminescence (ECL; Amersham).
Transmission electron microscopy
CsCl gradient-purified and dialysed samples were
mounted onto carbon-coated grids, stained with 2% am-
monium molybdate, pH 6.2, and examined with an Hita-
chi H-800 electron microscope.
Immunisation of mice
Four- to 8-week-old female mice were immunised on
Days 0 and 21 with 50 mg of VLPs intranasally. Alterna-
tively, mice were immunised intramuscularly and
boosted at Day 21. Sera and mucosal secretions were
collected after a further 7 days and stored at 270°C until
use. Vaginal secretions were collected by washing the
vaginal tracts with 100 ml of sterile PBS, and respiratory
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secretions were collected by repeatedly flushing the
lungs with 300 ml sterile PBS 7 days after a booster
immunisation as previously described (VanCott et al.,
1998). The vaginal and lung washes were cleared by
centrifugation at 13,000 rpm to remove any tissue and
cellular debris and stored at 270°C until analyzed. For
the hemagglutination inhibition assay, the washes were
incubated in a 56°C water bath for 30 min before testing.
Cytotoxic T lymphocyte assays
Mice immunised as described above were sacrificed
on Day 35, spleens were removed, and a single cell
suspension of spleen cells was cultured in complete
RMPI 1640 medium supplemented with 10 m/ml rIL-2
(Sigma) for 3 days. For HPV-E7-specific CTL assays, EL4
or EL4.E7 target cells were washed once with serum-free
complete RPMI and labeled with 100 mCi of 51Cr/107
cells. Excess 51Cr was removed using the FBS underlay
technique. Effector cells and labeled target cells were
plated into 96-well round-bottom plates at various effec-
tor/target ratios and incubated at 37°C, 5% CO2 for 5 h.
Supernatant (100 ml) was collected from each well for
counting with a gamma counter. The percentage of spe-
cific lysis was calculated as specific lysis 5 (sample
release 2 spontaneous release)/(maximum release 2
spontaneous release) 3 100. Maximum release was
generated by adding 100 ml of 10% SDS to 100 ml of
target cells, and spontaneous release was assayed from
100 ml of target cells incubated with 100 ml of medium.
Assays were performed in triplicate, and spontaneous
51Cr release from the various targets did not exceed 15%.
Each set of results represents the means from two inde-
pendent experiments.
T proliferation response assay
T proliferation assays were carried out as described
(Tindle et al., 1991). In brief, splenocyte suspensions
were treated with an NH4Cl solution to lyse the red blood
cells. White blood cells were harvested by centrifugation
at 800 rpm for 5 min and were washed three times with
DMEM without FCS. The washed cells were resus-
pended in 20 ml of complete DMEM with 10% FCS and
diluted to a concentration of 106 cells/ml. Cell suspen-
sion (200 ml) was added to each well of 96-well tissue-
culture plates. Cells in test wells were stimulated by
addition of antigen in a total volume of 10–20 ml/well,
using four replicates, for 4 days in a humidified tissue-
culture incubator. Cellular proliferation was assessed by
the incorporation of [3H]thymidine at 0.4 mCi/well over a
period of 18 h. The stimulation index (SI) was calculated
as the ratio of the mean counts per minute of [3H]thymi-
dine incorporated in the presence of stimulating anti-
gens or peptides to the mean counts per minute of
incorporated [3H]thymidine obtained in the absence of
stimulating antigens.
ELISA assays for anti-VLP IgA and serum IgG
Measurements of total and VLP-specific IgA in serum,
lung and vaginal secretions were performed in flat-bot-
tom microtitre plates, as previously described (Peng et
al., 1998). Briefly, a rabbit anti-BPV1 antiserum (Peng et
al., 1998) was used to coat the plates. After blocking with
5% milk/PBS, 50 ml BPV1L1/E7 VLPs at a concentration of
10 mg/ml was added to each well and incubated at 37°C
for 90 min. Sera and mucosal washes were tested by
twofold serial dilution in 5% milk/PBS. Bound antibody
was detected with horseradish peroxidase-conjugated
sheep anti-mouse IgG and goat anti-mouse IgA a chain,
at a dilution of 1:1000, followed by incubation with OPD in
the presence of hydrogen peroxide. The reaction was
stopped with 3 N HCl and absorbances were measured
at 450 nm.
Hemagglutination inhibition assay
The method used was as previously described (Roden
et al., 1995). Fresh mouse blood (1 ml) was collected in a
tube containing 1000 units of heparin. The blood sample
was suspended in 9 ml of PBS and 1 mg BSA and
centrifuged at 1500 rpm for 5 min. The supernatant was
aspirated, and the red blood cells (RBC) were resus-
pended in 10 ml PBS and 1 mg BSA and centrifuged at
1500 rpm for 5 min. After being washed three times, the
final RBC pellet was diluted to 1% (v/v) in PBS 1 1 mg/ml
BSA. One hundred microliters of this RBC suspension
was mixed with the same volume of BPV1L1/E7 VLPs
and added to a 96-well round-bottom plate, incubated at
4°C for 3 h, and photographed. For the antibody inhibi-
tion assay, the sera were incubated with 4 vol of 25% v/v
mouse RBC overnight at 4°C, and cleared by centrifuga-
tion at 1000 rpm at 4°C. The sera and mucosal washes
were heat-inactivated at 56°C for 30 min and incubated
with BPVL1/E7 VLPs at room temperature for 1 h with
gentle rocking, before mixing with mouse RBCs.
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